FibroGen ( ($FGEN) ) just unveiled an announcement. On August 18, 2025, FibroGen announced that it received regulatory approval from the China ...

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now ...

Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Marke ...

Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30. Investors in FibroGen are eagerly awaiting the ...

Gain insights into FibroGen’s Q2 2025 earnings call, highlighting trial progress, regulatory updates, and increased cash runway.

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now esti ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

Investing.com -- FibroGen Inc (NASDAQ: FGEN) stock jumped 9.9% following positive feedback from the U.S. Food and Drug Administration supporting the advancement of roxadustat for treating anemia in ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.